Not All AI Is Created Equal: Exploring the Value of AI, ML, and Agents in Clinical Trial Intelligence

AI has become a catch-all term applied to everything from a smart autocomplete field in an EDC system to a fully autonomous AI agent that can close data queries, flag risk signals, and generate regulatory-ready outputs without human intervention. Unfortunately, when everything is AI, it’s difficult to identify which AI tool will truly make a difference to clinical trial efficiency. Organizations end up either over-investing in the wrong tools or dismissing legitimate AI entirely because they have been burned by overpromised “AI-powered” features that turned out to be glorified keyword matching.

The inability to distinguish between types of AI is a strategic problem. It leads to misaligned investments, underdelivered promises, and missed opportunities that show up as competitive disadvantage two years later.

What the field needs is a clear taxonomy. Four distinct layers. Each with its own use cases, data requirements, and governance expectations.

Layer 1: Descriptive Analytics, the Foundation You Already Have

While not AI in the modern sense, descriptive analytics is where most clinical data intelligence begins. Descriptive analytics evaluates your clinical data and answers the question: What happened?

In clinical data, this type of AI includes dashboards showing query rates by site, enrollment velocity by country, and data entry lag by visit. It includes standard reports generated from SDTM datasets and the operational metrics a data management lead reviews every Monday morning.

Vendors routinely label their dashboarding tools “AI-powered” when they are, in fact, running aggregated queries against a database. While there is nothing semantically wrong with this designation, it creates false expectations when the same label is applied to a predictive model or an autonomous agent.

If your AI tool only shows you what already happened and cannot tell you what to do about it, you have descriptive analytics.

Layer 2: Predictive Models, Machine Learning Applied

Predictive AI answers: What is likely to happen next?

This is where machine learning begins to deliver real value in clinical data management. Concrete examples include:

• anomaly detection models trained on historical query patterns that flag unusual data submissions before manual review begins,
• site risk models that identify facilities trending toward elevated protocol deviation rates based on enrollment velocity and query response time,
• and patient dropout prediction that surfaces early warning signals for medical monitors before a subject is lost.

Predictive models require two things your organization may or may not have: sufficient historical data to train on and a governed pipeline that continuously updates the model as new data arrives. This is why the data architecture question, covered in Post 1 of this series is a prerequisite, not an optional upgrade. You cannot run a reliable predictive model on fragmented, manually consolidated data.

Layer 3: Generative AI, the New Cognitive Layer

Generative AI answers: What should I create or communicate based on this context?

This is the layer that has captured the most executive attention since 2023 and for understandable reasons. In clinical data management, practical generative AI applications include:

• automated data query drafting, where a model writes a natural-language query explanation to sites based on a detected discrepancy,
• SDTM mapping narrative generation for regulatory submission packages,
• and plain-language summaries of protocol deviations for clinical study reports.

In a regulated environment, generative AI requires explicit governance: model validation documentation, human review workflows with clear sign-off authority, and audit-ready records of what the model produced versus what a human approved. The regulatory community is actively developing frameworks here. ICH is working on guidance updates that will touch AI-generated content, and the FDA’s discussion paper on AI and ML in drug development signals the direction of travel. Organizations moving fast on generative AI without governance frameworks will pay the price at inspection, not at deployment.

Layer 4: Agentic AI, the Autonomous Operator

Agentic AI answers: What action should I take, and can I take it without waiting for a human?

This is the frontier, and where the most transformative value lies. An AI agent in clinical data management is not just a model that produces an output. It is a system that perceives its environment, reasons through it, decides on an action, and executes, sometimes without human initiation.

Here are examples of clinical data agents already in deployment or active development in the elluminate^® Clinical Data Intelligence Platform:

• Data Mapping Agent: Autonomously maps incoming vendor data to SDTM standards, scores each decision by confidence, flags ambiguous fields for human review, and updates the mapping library with every approved decision, getting smarter with each study.
• Data Review Agent: Continuously reviews incoming data against edit checks, generates queries, follows up on unresolved queries after defined intervals, and escalates based on clinical significance tier, without waiting for a data manager to open a review queue.
• RBQM Agent: Monitors key risk indicators in real time, automatically adjusts monitoring intensity for sites based on emerging signals, and notifies clinical monitors when thresholds are crossed, replacing the weekly manual KRI review with continuous, responsive oversight.
• Study Operations Agent: Tracks study milestones, forecasts database lock dates based on query resolution velocity, and surfaces resource constraint alerts to study management before they become timeline problems.

The Decision Framework: Three Questions Before You Buy

When evaluating any AI capability, whether from a vendor or an internal development team, ask these three questions before signing anything:

• What question is this system answering? What happened / What will happen / What should I create / What should I do. The answer tells you exactly which layer you are buying, regardless of how it is marketed.
• What does it require to function? Historical training data, real-time data pipelines, a generative model, or action execution capability. If the vendor cannot answer this specifically, the product is not ready.
• What does your regulatory environment require for this type of AI? Audit trail, validation documentation, human review workflows, model performance monitoring. Requirements escalate significantly as you move up the taxonomy, an RBQM agent that makes autonomous monitoring decisions carries far more regulatory weight than a dashboard.

Clarity on these three questions will save you from buying Layer 1 capabilities at Layer 4 prices and from being caught unprepared when a regulatory inspector asks how a decision was made.

Learn more about elluminate’s AI agents.